3 Stocks Screening Well for Obesity Drug Supply Chain Exposure

Novo Nordisk just reminded investors that even market darlings tied to obesity drugs come with patent clocks and confidence shocks. That mix of excitement around GLP‑1 treatments and fresh concern about long term growth plans is creating rapid repricing across anything linked to obesity and metabolic disease. This article walks through three stocks exposed to that same news and explains why each could offer either opportunity or a useful warning sign.

The stocks covered next are only a small sample of what Novo Nordisk has pulled into focus, and the same screen on Simply Wall St surfaced 14 more large and mid cap healthcare players with obesity and metabolic narratives that this article does not touch. To identify and analyze those extra opportunities with consistent filters, head straight into the Global Obesity & Metabolic Disease Treatments screener.

PolyPeptide Group (SWX:PPGN)

PolyPeptide Group gives you a way into the obesity and metabolic drug theme through the picks and shovels of peptide manufacturing, with its CDMO model closely tied to GLP‑1 programs while still serving a broader mix of peptide therapies worldwide.

PolyPeptide Group develops and manufactures synthetic peptides for drugmakers, with about €275 million from commercial contracts and €184 million from development work, and the stock valued at roughly CHF 1.5b by the market.

"The rapid shift of the portfolio toward metabolics, where revenues have tripled since 2021 and now account for more than half of group sales, positions the company in an area management describes as the main growth engine for peptides."

What happens to that engine depends heavily on how one powerful pressure on future manufacturing economics plays out from here.

That pressure point is exactly where the story gets interesting, and the full narrative for PolyPeptide Group unpacks how PolyPeptide Group’s metabolics pivot could either accelerate or stall from here.

Hua Medicine (Shanghai) (SEHK:2552)

Hua Medicine (Shanghai) plugs straight into the obesity and metabolic disease theme through its focus on type 2 diabetes drugs, giving you a China based pure play that is already commercial and looking to extend its reach across related metabolic conditions.

"Expansion of dorzagliatin into Hong Kong and Macao, together with interest from Southeast Asia, Belt and Road regions and Portuguese speaking markets, creates a pathway from a China focused franchise to a broader international footprint."

If a single pricing and reimbursement assumption shifts, the impact on future dorzagliatin margins and Hua Medicine (Shanghai)’s earnings profile could be significant.

Hua Medicine (Shanghai) develops and sells dorzagliatin based diabetes treatments within China, generating about CN¥654 million from pharmaceuticals revenue, and the stock is valued at roughly HK$2.3b by the market.

That pricing swing is exactly what the full narrative for Hua Medicine (Shanghai) tackles, highlighting where dorzagliatin economics could accelerate, stall or be quietly reshaped by international expansion plans.

Biocon (NSEI:BIOCON)

Biocon plugs into the obesity and metabolic disease story through its diabetes and obesity related generics and biosimilars, while still being a diversified biopharma group spanning oncology drugs and research services.

Biocon generates about ₹108.3b from biosimilars, ₹36b from services and ₹33b from generics, and the stock is valued at roughly ₹623.5b by the market.

For investors watching how obesity and diabetes treatments ripple through the wider drug supply chain, Biocon offers exposure at the biosimilar and generic GLP‑1 level rather than through a single headline obesity brand.

"The accelerating pace of product pipeline execution, including multiple global biosimilar launches, novel specialty generics such as GLP‑1s and upcoming filings in large markets (e.g., U.S. and EU for liraglutide, semaglutide), is described by some analysts as positioning Biocon to capture a substantial share of the multi‑billion‑dollar opportunity from major biologic patent expiries, supporting prospects for revenue growth and operating leverage."

What investors really have to weigh now is how one untested pressure on future pricing and margins plays out as those opportunities scale.

If that pricing squeeze is what you are trying to size up, the full narrative for Biocon maps where Biocon’s GLP-1 ambitions and margin risks could realistically converge.

Seeking Alternatives Before The Crowd?

Fresh themes gain momentum fast, and the strongest ideas rarely stay under the radar for long. Before the next breakout gets fully priced in, get in early.

• Target sturdier portfolios by scanning a curated list of solid balance sheet and fundamentals (198 results) that aims to highlight businesses built to handle shocks while weaker peers are still dropping.
• Ride structural tailwinds as power demand keeps climbing by checking the hand picked 39 power grid technology and infrastructure stocks while these infrastructure stories are under the radar for now.
• Catch early demand surges in automation by reviewing carefully filtered 96 robotics and automation stocks before momentum traders crowd into the fastest moving robotics suppliers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com